Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) EBT Margin (2016 - 2025)

Historic EBT Margin for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to 953.4%.

  • Pharma's EBT Margin fell 5366600.0% to 953.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 582.82%, marking a year-over-year increase of 4796500.0%. This contributed to the annual value of 560.27% for FY2025, which is 4062800.0% up from last year.
  • As of Q3 2025, Pharma's EBT Margin stood at 953.4%, which was down 5366600.0% from 487.5% recorded in Q2 2025.
  • Pharma's 5-year EBT Margin high stood at 362.73% for Q1 2025, and its period low was 7757.14% during Q3 2021.
  • Moreover, its 5-year median value for EBT Margin was 977.97% (2024), whereas its average is 1847.1%.
  • Within the past 5 years, the most significant YoY rise in Pharma's EBT Margin was 72351200bps (2021), while the steepest drop was -64315400bps (2021).
  • Quarter analysis of 5 years shows Pharma's EBT Margin stood at 1676.76% in 2021, then soared by 60bps to 677.41% in 2022, then plummeted by -304bps to 2739.71% in 2023, then soared by 74bps to 711.67% in 2024, then tumbled by -34bps to 953.4% in 2025.
  • Its EBT Margin stands at 953.4% for Q3 2025, versus 487.5% for Q2 2025 and 362.73% for Q1 2025.